Dyadic, Proliant launch recombinant human albumin

Profit-sharing deal puts Dyadic's fungal tech to work as Proliant launches AlbuFree DX albumin, with a cell culture version expected later this year.

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

Dyadic Applied BioSolutions and Proliant Health & Biologicals have announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic's proprietary filamentous fungal expression technology. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant's commercial sales of recombinant human albumin products.

Why it matters

Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree™ DX marks the first major commercial step in Dyadic's growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.

The details

The launch of AlbuFree™ DX underscores Dyadic's strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Proliant has decades of experience producing albumin at global scale and supplying customers through an established worldwide distribution network. AlbuFree™ DX builds on that foundation by adding a high-quality, animal-free recombinant human albumin to Proliant's diagnostic market portfolio, allowing them to meet growing customer demand while maintaining the consistency, reliability, and scale their customers expect.

  • The commercial launch of AlbuFree™ DX occurred on February 17, 2026.

The players

Dyadic Applied BioSolutions

A global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets.

Proliant Health & Biologicals

A global leader in the production of purified bovine and recombinant proteins, serving life science, diagnostic, nutrition, and medical markets worldwide.

Joe Hazelton

President and Chief Operating Officer of Dyadic.

Chris Detzel

President and Chief Executive Officer of Proliant Health & Biologicals.

Got photos? Submit your photos here. ›

What they’re saying

“This launch is a clear validation of Dyadic's technology and our commercialization strategy. Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”

— Joe Hazelton, President and Chief Operating Officer of Dyadic (stocktitan.net)

“Proliant has decades of experience producing albumin at global scale and supplying customers through an established worldwide distribution network. AlbuFree™ DX builds on that foundation by adding a high-quality, animal-free recombinant human albumin to our diagnostic market portfolio, allowing us to meet growing customer demand while maintaining the consistency, reliability, and scale our customers expect.”

— Chris Detzel, President and Chief Executive Officer of Proliant Health & Biologicals (stocktitan.net)

What’s next

Further expansion of the AlbuFree™ line is expected later this year with the next version specifically formulated for the cell culture market.

The takeaway

This milestone demonstrates that Dyadic's microbial platforms are well-suited for products that can be efficiently integrated into existing manufacturing, quality, and commercial infrastructures, reinforcing the applicability of Dyadic's technology for scalable commercialization in large, established markets.